• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Hematopoietic SH2 domain-containing protein (HSH2D)

ACP13187

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP13187 Target NameHSH2D
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Expression Range1-352Protein LengthFull length protein
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ96JZ2
Background Information
  • Uniprot Id

    Q96JZ2

  • Target Species

    Human

  • Target Name

    HSH2D

  • Target Full Name

    Hematopoietic SH2 domain-containing protein

  • Target Function

    May be a modulator of the apoptotic response through its ability to affect mitochondrial stability. Adapter protein involved in tyrosine kinase and CD28 signaling. Seems to affect CD28-mediated activation of the RE/AP element of the interleukin-2 promoter.

  • Target Subcellular Location

    Cytoplasm. Nucleus.

  • Target Tissue Specificity

    Predominantly expressed in spleen and hematopoietic cells such as peripheral blood leukocytes and weakly expressed in prostate, thymus, heart, small intestine and placenta.

  • Target Synonyms

    Adaptor in lymphocytes of unknown function X; ALX ; FLJ14886; hematopoietic SH2 domain containing; Hematopoietic SH2 domain containing protein; Hematopoietic SH2 domain-containing protein; Hematopoietic SH2 protein; HSH2 ; Hsh2d; HSH2D_HUMAN

Inquire Recombinant Human Hematopoietic SH2 domain-containing protein (HSH2D) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification